Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians

被引:47
作者
Marinaki, AM
Arenas, M
Khan, ZH
Lewis, CM
Shobowale-Bakre, EM
Escuredo, E
Fairbanks, LD
Mayberry, JF
Wicks, AC
Ansari, A
Sanderson, J
Duley, JA
机构
[1] Guys & St Thomas Hosp, Dept Gastroenterol, London SE1 9RT, England
[2] Leicester Gen Hosp, Dept Gastroenterol, Leicester LE5 4PW, Leics, England
[3] Kings Coll London, GKT Sch Med, Div Genet & Dev, London WC2R 2LS, England
来源
PHARMACOGENETICS | 2003年 / 13卷 / 02期
关键词
thiopurine; azathioprine; 6-mercaptopurine; variable number terminal repeat; VNTR; thiopurine methyltransferase; TPMT; genotype; phenotype;
D O I
10.1097/00008571-200302000-00006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective Polymorphisms in the TPMT gene open reading frame (ORF) are associated with reduced TPMT activity. Variable number tandem repeats (VNTR*3 to VNTR*9) in the promoter region of the gene consisting of combinations of Type A, B and C repeat units, may modulate TPMT activity. Here we present the allele frequencies of genetic modifiers of TPMT activity in a British Asian population, as well as the concordance between intermediate TPMT activity and ORF and VNTR genotypes in a predominantly Caucasian population. Methods VNTR type and ORF mutations were determined in two selected TPMT activity ranges, intermediate activity (4-8 U, 108 patients), normal (112-15 U, 53 patients) and in 85 British Asians. Results In British Asians, TPMT*3C was the prevalent mutant allele (four heterozygotes). One patient was heterozygous for TPMT*3A. Overall VNTR frequencies did not differ from Caucasians. Three new VNTR alleles were designated VNTR*6c, VNTR*6d, and VNTR*7c. Forty-one percent of patients with intermediate activity were heterozygous for a TPMT ORF mutation (3A, 2B, 1C). Marked linkage disequilibrium was noted between VNTR*6b - TPMT*3A (D' = 1), VNTR*4b - TPMT*3C (D' = 0.67) and VNTR*6a - TPMT*1 (D' = 1) alleles. As a result, significant differences (P < 0.05) in the distribution of Type A, B or the total number of repeats summed for both alleles, were found between the ORF heterozygous intermediate activity group and the wild-type intermediate or normal activity groups. No significant difference was; found between the two wild-type groups. Conclusion Our results suggest that TPMT gene VNTRs do not significantly modulate enzyme activity.
引用
收藏
页码:97 / 105
页数:9
相关论文
共 45 条
[31]   Human thiopurine methyltransferase activity varies with red blood cell age [J].
Lennard, L ;
Chew, TS ;
Lilleyman, JS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (05) :539-546
[32]   Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway [J].
Loennechen, T ;
Utsi, E ;
Hartz, I ;
Lysaa, R ;
Kildalsen, H ;
Aarbakke, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) :183-188
[33]   Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals [J].
McLeod, HL ;
Pritchard, SC ;
Githang'a, J ;
Indalo, A ;
Ameyaw, MM ;
Powrie, RH ;
Booth, L ;
Collie-Duguid, ESR .
PHARMACOGENETICS, 1999, 9 (06) :773-776
[34]   Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms [J].
Otterness, D ;
Szumlanski, C ;
Lennard, L ;
Klemetsdal, B ;
Aarbakke, J ;
ParkHah, JO ;
Iven, H ;
Schmiegelow, K ;
Branum, E ;
OBrien, J ;
Weinshilboum, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) :60-73
[35]   Human thiopurine methyltransferase pharmacogenetics - Kindred with a terminal exon splice junction mutation that results in loss of activity [J].
Otterness, DM ;
Szumlanski, CL ;
Wood, TC ;
Weinshilboum, RM .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (05) :1036-1044
[36]   Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus [J].
Relling, MV ;
Hancock, ML ;
Rivera, GK ;
Sandlund, JT ;
Ribeiro, RC ;
Krynetski, EY ;
Pui, CH ;
Evans, WE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (23) :2001-2008
[37]  
REMY CN, 1963, J BIOL CHEM, V238, P1078
[38]  
Schaeffeler E, 2001, CLIN CHEM, V47, P548
[39]   Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism [J].
Szumlanski, C ;
Otterness, D ;
Her, C ;
Lee, D ;
Brandriff, B ;
Kelsell, D ;
Spurr, N ;
Lennard, L ;
Wieben, E ;
Weinshilboum, R .
DNA AND CELL BIOLOGY, 1996, 15 (01) :17-30
[40]   SULFASALAZINE INHIBITION OF THIOPURINE METHYLTRANSFERASE - POSSIBLE MECHANISM FOR INTERACTION WITH 6-MERCAPTOPURINE AND AZATHIOPRINE [J].
SZUMLANSKI, CL ;
WEINSHILBOUM, RM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (04) :456-459